Risultati per: Tumore colon: trovate le cellule che formano le metastasi

Studio, dieta anti cancro da cereali integrali e verdura

Oncologi, la preservazione della fertilità tra le nuove problematiche

Studio Gemelli-Cattolica su 35 pazienti in fase avanzata

Studio, dieta anti cancro da cereali integrali e verdura

‘Regioni individuino i laboratori per l’esecuzione dell’esame’

Per un aggiornamento continuo su ricerca e approcci terapeutici

Senza aumento delle false diagnosi. Uno in più per 1.000 individui

L’operazione è durata due ore, al Policlinico di Milano

The prospect of avoiding an invasive colonoscopy has helped fuel interest around new less-invasive alternatives to colorectal cancer screenings, such as stool-based tests and cell-free blood-based DNA tests, which received approval from the US Food and Drug Administration (FDA) this past July. But traditional colonoscopies remain the best method for catching colorectal cancer early, according to a study published in the Annals of Internal Medicine.

Analisi potrebbe individuare primissimi segni cellule cancerose

Studio internazionale guidato da una ricercatrice di Pavia

Il programma viene esteso fino alla fascia 70-74 anni

Introduction
The standard of care for stage III colon cancer is 3 or 6 months of double-drug regimen chemotherapy following radical surgery. However, patients with positive circulating tumour DNA (ctDNA) exhibit a high risk of recurrence risk even if they receive standard adjuvant chemotherapy. The potential benefit of intensified adjuvant chemotherapy, oxaliplatin, irinotecan, leucovorin and fluoropyrimidine (FOLFOXIRI), for ctDNA-positive patients remains to be elucidated.

Methods and analysis
This multicentre phase II randomised controlled trial aims to investigate the utility of ctDNA in monitoring chemosensitivity and to preliminarily assess whether intensified chemotherapy with FOLFOXIRI can increase ctDNA clearance and improve survival outcomes. A total of 60 eligible patients with stage III colon cancer exhibiting postoperatively positive ctDNA before and after two cycles of oxaliplatin and capecitabine (XELOX) will be randomly assigned to continue five additional cycles of XELOX (control arm) or switch to eight cycles of FOLFOXIRI (experimental arm). This sequential approach is designed to escalate treatment for patients with persistent ctDNA positivity while avoiding overtreatment in those who may respond well to standard chemotherapy. The primary endpoint is the change in ctDNA concentration, defined as the difference between the ctDNA concentration measured after two cycles of XELOX and after the completion or termination of chemotherapy. Secondary endpoints include the ctDNA clearance rate, 2-year disease-free survival, distant metastasis-free survival, chemotherapy-related side effects and quality of life.

Ethics and dissemination
This trial has been approved by the Ethics Committee of the West China Hospital, Sichuan University (approval number: 20231998). The findings will be disseminated through peer-reviewed publications and presentations at scientific conferences.

Trial registration number
ClinicalTrials.gov (NCT06242418, registered on 27 January 2024).

Efficace anticorpo-farmaco. Curigliano: ‘Risposta intorno al 60%’

Domani ad Ancona congresso scientifico alla Politecnica Marche